drugset / Trial / NCT02237183

Iloprost in Preventing Lung Cancer in Former Smokers

NCT02237183

Phase 1 Completed 34 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupDouble-blindPrevention

Summary

This phase I trial studies the side effects and best dose of iloprost compared with a placebo in preventing lung cancer in former smokers. Chemoprevention is the use of drugs to keep cancer from forming or coming back. Inhaled iloprost may help prevent lung cancer from forming in patients who used to smoke and who have been found to have abnormal cells in their mucus.

Timeline

Start
2015-11-05
Primary completion
2020-03-05
Completion
2023-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloprost Other / unclassified Inhaled

Indications